Purple Biotech (PPBT) Competitors $2.53 -0.12 (-4.53%) Closing price 04/29/2025 03:54 PM EasternExtended Trading$2.40 -0.13 (-5.10%) As of 04/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PPBT vs. MBRX, TRIB, CLDI, CLRB, ABP, MRKR, NRSN, ME, MEIP, and SYBXShould you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Moleculin Biotech (MBRX), Trinity Biotech (TRIB), Calidi Biotherapeutics (CLDI), Cellectar Biosciences (CLRB), Abpro (ABP), Marker Therapeutics (MRKR), NeuroSense Therapeutics (NRSN), 23andMe (ME), MEI Pharma (MEIP), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. Purple Biotech vs. Moleculin Biotech Trinity Biotech Calidi Biotherapeutics Cellectar Biosciences Abpro Marker Therapeutics NeuroSense Therapeutics 23andMe MEI Pharma Synlogic Moleculin Biotech (NASDAQ:MBRX) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, community ranking, institutional ownership, risk, valuation, analyst recommendations and earnings. Does the MarketBeat Community favor MBRX or PPBT? Moleculin Biotech received 214 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 94.44% of users gave Purple Biotech an outperform vote while only 49.36% of users gave Moleculin Biotech an outperform vote. CompanyUnderperformOutperformMoleculin BiotechOutperform Votes23149.36% Underperform Votes23750.64% Purple BiotechOutperform Votes1794.44% Underperform Votes15.56% Do analysts rate MBRX or PPBT? Moleculin Biotech currently has a consensus price target of $6.00, suggesting a potential upside of 488.24%. Purple Biotech has a consensus price target of $33.00, suggesting a potential upside of 1,204.35%. Given Purple Biotech's higher possible upside, analysts plainly believe Purple Biotech is more favorable than Moleculin Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of MBRX or PPBT? 15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 1.9% of Moleculin Biotech shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to MBRX or PPBT? In the previous week, Moleculin Biotech had 1 more articles in the media than Purple Biotech. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 0.94 beat Moleculin Biotech's score of 0.62 indicating that Purple Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Purple Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, MBRX or PPBT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$29.77MN/AN/APurple BiotechN/AN/A-$19.88M-$5.25-0.48 Which has more volatility and risk, MBRX or PPBT? Moleculin Biotech has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Is MBRX or PPBT more profitable? Purple Biotech's return on equity of -55.86% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -157.44% -97.16% Purple Biotech N/A -55.86%-44.67% SummaryPurple Biotech beats Moleculin Biotech on 7 of the 12 factors compared between the two stocks. Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PPBT vs. The Competition Export to ExcelMetricPurple BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.37M$6.79B$5.51B$7.83BDividend YieldN/A3.09%5.11%4.23%P/E Ratio-0.297.3322.4018.52Price / SalesN/A240.73399.74103.32Price / CashN/A65.8538.1834.62Price / Book0.096.396.744.24Net Income-$19.88M$142.94M$3.22B$248.05M7 Day Performance-7.80%2.13%2.40%3.18%1 Month Performance-8.99%-1.61%-0.83%1.69%1 Year PerformanceN/A1.68%17.79%5.93% Purple Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PPBTPurple Biotech2.5737 of 5 stars$2.53-4.5%$33.00+1,204.3%N/A$3.37MN/A-0.2920Gap DownMBRXMoleculin Biotech3.0054 of 5 stars$0.99-6.9%$6.00+508.1%-79.6%$13.81MN/A0.0020Short Interest ↓Gap UpTRIBTrinity Biotech1.5921 of 5 stars$0.76+7.3%N/A-55.1%$13.72M$59.13M-0.34480Short Interest ↓Gap UpCLDICalidi Biotherapeutics2.1718 of 5 stars$0.48-0.3%$15.00+3,014.0%N/A$13.71M$50,000.000.0038CLRBCellectar Biosciences1.8372 of 5 stars$0.30-4.4%$12.50+4,117.3%-90.6%$13.66MN/A-0.1710Analyst ForecastNews CoverageABPAbproN/A$0.26-18.0%$4.00+1,434.3%N/A$13.61M$183,000.000.0015News CoverageGap DownHigh Trading VolumeMRKRMarker Therapeutics4.4925 of 5 stars$1.26+0.8%$13.17+945.0%-70.4%$13.49M$6.59M-1.0560Short Interest ↓Positive NewsNRSNNeuroSense Therapeutics1.1505 of 5 stars$0.98-2.1%N/A-24.8%$13.38MN/A-1.5310Short Interest ↓ME23andMe0.2894 of 5 stars$0.50-35.3%N/A-95.2%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeMEIPMEI Pharma1.6255 of 5 stars$1.99-5.2%N/A-33.9%$13.26M$65.30M-0.35100Short Interest ↑Gap UpSYBXSynlogic2.4732 of 5 stars$1.12-3.8%N/A-39.0%$13.10M$8,000.00-0.2780Short Interest ↓Positive News Related Companies and Tools Related Companies Moleculin Biotech Competitors Trinity Biotech Competitors Calidi Biotherapeutics Competitors Cellectar Biosciences Competitors Abpro Competitors Marker Therapeutics Competitors NeuroSense Therapeutics Competitors 23andMe Competitors MEI Pharma Competitors Synlogic Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PPBT) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Silent Heist Draining Your Retirement SavingsU.S. Debt Crisis - A Silent Heist of Your Retirement Savings Americans are losing wealth daily and don't ev...American Hartford Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PPBT Stock Free PPBT Stock Alerts